Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2006 (2006), Article ID 83084, 5 pages
http://dx.doi.org/10.1155/IDOG/2006/83084
Clinical Study

Reducing the Health Burden of HPV Infection Through Vaccination

Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston 29425, SC, USA

Received 18 August 2005; Accepted 20 September 2005

Copyright © 2006 David Soper. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W Jr Cates, “Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel,” Sexually Transmitted Diseases, vol. 26, no. 4 suppl, pp. S2–S7, 1999. View at Publisher · View at Google Scholar · View at PubMed
  2. H Weinstock, S Berman, and W Jr Cates, “Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000,” Perspectives on Sexual and Reproductive Health, vol. 36, no. 1, pp. 6–10, 2004. View at Publisher · View at Google Scholar · View at PubMed
  3. R D Burk, P Kelly, J Feldman et al., “Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors,” Sexually Transmitted Diseases, vol. 23, no. 4, pp. 333–341, 1996. View at Google Scholar · View at PubMed
  4. N Muñoz, F X Bosch, S de Sanjosé et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003. View at Google Scholar · View at PubMed
  5. C L Peyton, P E Gravitt, W C Hunt et al., “Determinants of genital human papillomavirus detection in a US population,” The Journal of Infectious Diseases, vol. 183, no. 11, pp. 1554–1564, 2001. View at Publisher · View at Google Scholar · View at PubMed
  6. D R Brown, J M Schroeder, J T Bryan, M H Stoler, and K H Fife, “Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients,” Journal of Clinical Microbiology, vol. 37, no. 10, pp. 3316–3322, 1999. View at Google Scholar · View at PubMed
  7. L A Koutsky, D A Galloway, and K K Holmes, “Epidemiology of genital human papillomavirus infection,” Epidemiologic Reviews, vol. 10, pp. 122–163, 1988. View at Google Scholar · View at PubMed
  8. D M Harper, “Why am I scared of HPV?,” CA: A Cancer Journal for Clinicians, vol. 54, no. 5, pp. 245–247, 2004. View at Google Scholar · View at PubMed
  9. J M Walboomers, M V Jacobs, M M Manos et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” The Journal of Pathology, vol. 189, no. 1, pp. 12–19, 1999. View at Publisher · View at Google Scholar · View at PubMed
  10. C Ley, H M Bauer, A Reingold et al., “Determinants of genital human papillomavirus infection in young women,” Journal of the National Cancer Institute, vol. 83, no. 14, pp. 997–1003, 1991. View at Publisher · View at Google Scholar · View at PubMed
  11. G Y Ho, R Bierman, L Beardsley, C J Chang, and R D Burk, “Natural history of cervicovaginal papillomavirus infection in young women,” The New England Journal of Medicine, vol. 338, no. 7, pp. 423–428, 1998. View at Publisher · View at Google Scholar · View at PubMed
  12. J W Sellors, T L Karwalajtys, J Kaczorowski et al., “Incidence, clearance and predictors of human papillomavirus infection in women,” CMAJ: Canadian Medical Association Journal, vol. 168, no. 4, pp. 421–425, 2003. View at Google Scholar · View at PubMed
  13. R D Burk, G Y Ho, L Beardsley, M Lempa, M Peters, and R Bierman, “Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women,” The Journal of Infectious Diseases, vol. 174, no. 4, pp. 679–689, 1996. View at Google Scholar · View at PubMed
  14. L E Manhart and L A Koutsky, “Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis,” Sexually Transmitted Diseases, vol. 29, no. 11, pp. 725–735, 2002. View at Publisher · View at Google Scholar · View at PubMed
  15. C J Hogewoning, M C Bleeker, and A J van den Brule, “Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial,” International Journal of Cancer, vol. 107, no. 5, pp. 811–816, 2003. View at Publisher · View at Google Scholar · View at PubMed
  16. R P Insinga, A G Glass, and B B Rush, “The health care costs of cervical human papillomavirus—related disease,” American Journal of Obstetrics and Gynecology, vol. 191, no. 1, pp. 114–120, 2004. View at Publisher · View at Google Scholar · View at PubMed
  17. H W Chesson, J M Blandford, T L Gift, G Tao, and K L Irwin, “The estimated direct medical cost of sexually transmitted diseases among American youth, 2000,” Perspectives on Sexual and Reproductive Health, vol. 36, no. 1, pp. 11–19, 2004. View at Publisher · View at Google Scholar · View at PubMed
  18. J Zhou, X Y Sun, D J Stenzel, and I H Frazer, “Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles,” Virology, vol. 185, no. 1, pp. 251–257, 1991. View at Publisher · View at Google Scholar · View at PubMed
  19. M E Hagensee, N Yaegashi, and D A Galloway, “Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins,” Journal of Virology, vol. 67, no. 1, pp. 315–322, 1993. View at Google Scholar · View at PubMed
  20. J T Schiller and P Davies, “Delivering on the promise: HPV vaccines and cervical cancer,” Nature Reviews. Microbiology, vol. 2, no. 4, pp. 343–347, 2004. View at Publisher · View at Google Scholar · View at PubMed
  21. J A Suzich, S J Ghim, F J Palmer-Hill et al., “Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 25, pp. 11553–11557, 1995. View at Publisher · View at Google Scholar · View at PubMed
  22. K U Jansen, M Rosolowsky, L D Schultz et al., “Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation,” Vaccine, vol. 13, no. 16, pp. 1509–1514, 1995. View at Publisher · View at Google Scholar · View at PubMed
  23. D V Pastrana, W C Vass, D R Lowy, and J T Schiller, “NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16,” Virology, vol. 279, no. 1, pp. 361–369, 2001. View at Publisher · View at Google Scholar · View at PubMed
  24. D Nardelli-Haefliger, D Wirthner, J T Schiller et al., “Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles,” Journal of the National Cancer Institute, vol. 95, no. 15, pp. 1128–1137, 2003. View at Google Scholar · View at PubMed
  25. C D Harro, Y Y Pang, R B Roden et al., “Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine,” Journal of the National Cancer Institute, vol. 93, no. 4, pp. 284–292, 2001. View at Publisher · View at Google Scholar · View at PubMed
  26. L A Koutsky, K A Ault, C M Wheeler et al., “A controlled trial of a human papillomavirus type 16 vaccine,” The New England Journal of Medicine, vol. 347, no. 21, pp. 1645–1651, 2002. View at Publisher · View at Google Scholar · View at PubMed
  27. D R Brown, J T Bryan, J M Schroeder et al., “Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer,” The Journal of Infectious Diseases, vol. 184, no. 9, pp. 1183–1186, 2001. View at Publisher · View at Google Scholar · View at PubMed
  28. K A Ault, A R Giuliano, R P Edwards et al., “A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine,” Vaccine, vol. 22, no. 23-24, pp. 3004–3007, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. K H Fife, C M Wheeler, L A Koutsky et al., “Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women,” Vaccine, vol. 22, no. 21-22, pp. 2943–2952, 2004. View at Publisher · View at Google Scholar · View at PubMed
  30. D M Harper, E L Franco, C M Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. L L Villa, R L Costa, C A Petta et al., “Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial,” The Lancet Oncology, vol. 6, no. 5, pp. 271–278, 2005. View at Publisher · View at Google Scholar · View at PubMed
  32. F E Skjeldestad, “ FUTURE II steering committee. Prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine (Gardasil) Reduces Cervical Intraepithelial Neoplasia (CIN) 2/3 Risk,” in Infectious Disease Society of America 43rd Annual Meeting, San Francisco, Calif, 2005, Abstract LB-8a. Available at: http://www.idsociety.org/Template.cfm?Section=Program2&CONTENTID=14108&TEMPLATE=/ContentManagement/ContentDisplay.cfm. Accessed at: January 16, 2006. View at Google Scholar
  33. G D Sanders and A V Taira, “Cost-effectiveness of a potential vaccine for human papillomavirus,” Emerging Infectious Diseases, vol. 9, no. 1, pp. 37–48, 2003. View at Google Scholar · View at PubMed
  34. A V Taira, C P Neukermans, and G D Sanders, “Evaluating human papillomavirus vaccination programs,” Emerging Infectious Diseases, vol. 10, no. 11, pp. 1915–1923, 2004. View at Google Scholar · View at PubMed
  35. J P Hughes, G P Garnett, and L A Koutsky, “The theoretical population-level impact of a prophylactic human papillomavirus vaccine,” Epidemiology, vol. 13, no. 6, pp. 631–639, 2002. View at Publisher · View at Google Scholar · View at PubMed
  36. H Baer, S Allen, and L Braun, “Knowledge of human papillomavirus infection among young adult men and women: implications for health education and research,” Journal of Community Health, vol. 25, no. 1, pp. 67–78, 2000. View at Publisher · View at Google Scholar · View at PubMed
  37. B Holcomb, J M Bailey, K Crawford, and M T IV Ruffin, “Adults' knowledge and behaviors related to human papillomavirus infection,” The Journal of the American Board of Family Practice, vol. 17, no. 1, pp. 26–31, 2004. View at Google Scholar · View at PubMed
  38. M Pitts and T Clarke, “Human papillomavirus infections and risks of cervical cancer: what do women know?,” Health Education Research, vol. 17, no. 6, pp. 706–714, 2002. View at Publisher · View at Google Scholar · View at PubMed
  39. D L Dell, H Chen, F Ahmad, and D E Stewart, “Knowledge about human papillomavirus among adolescents,” Obstetrics & Gynecology, vol. 96, no. 5 pt 1, pp. 653–656, 2000. View at Google Scholar · View at PubMed